Ignore These Risks to Gilead at Your Peril
Gilead Sciences (NASDAQ: GILD) has enjoyed remarkable success in the past year thanks to the launch of two instant billion-dollar blockbuster hepatitis C therapies, however, even best-in-breed biotech stocks like Gilead Sciences still face risks that could leave investors in the lurch. Read on to learn which three risks concern me most, and how they could impact Gilead Sciences down […]